Issues
-
Cover Image
Cover Image
ABOUT THE COVER
Chemokine and chemotactic receptor expression in nonhematopoietic cells can affect tumor formation, in part by altering the influx of innate immune cells into the tumor microenvironment (TME). Del Prete et al. investigate the link between mouse atypical chemotactic receptor CCRL2 expression in lung endothelial cells with immune surveillance of lung cancer and subsequent tumor formation. Knockout of CCRL2 in mice or antibody blockade of CCRL2 increases the establishment of lung cancer lesions, leading to poorer mouse survival, by inhibiting NK cell migration into the TME. CCRL2 expression is lower in patient lung tumor tissue compared to paired normal lung tissue, with low tumoral CCRL2 expression correlating to poorer patient survival. Read more starting on page 1775. Artwork is based on Figure 6D by the Sozzani laboratory. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
Cancer Immunology at the Crossroads
Cancer Immunology Miniatures
Anti–PD-1–Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients
Research Articles
Head and Neck Cancers Promote an Inflammatory Transcriptome through Coactivation of Classic and Alternative NF-κB Pathways
The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance
AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner
A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity
Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.